Dose titration based on safety and efficacy considerations is important to optimise patient response to therapy1,2
JAKAVI dosing may be adjusted during therapy based on changes in platelet count and response1
Dose adjustments during treatment by platelet count1

Recommended dose adjustments based on response1:
- The starting dose of JAKAVI should not be increased within the first 4 weeks of treatment and, thereafter, no more frequently than at 2-week intervals
- If efficacy is considered insufficient and platelet and neutrophil counts are adequate, the JAKAVI dose may be increased by a maximum of 5 mg twice daily
Dose titration is a critical component of optimal patient management
Continuing therapy with JAKAVI1
- Treatment may be continued as long as benefit-risk balance remains positive
- Following interruption or discontinuation of JAKAVI, symptoms of myelofibrosis may return over a period of approximately 1 week*
- Unless abrupt discontinuation is required, gradual tapering of the dose may be considered